{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:25:26Z","timestamp":1792218326765,"version":"4.4.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T00:00:00Z","timestamp":1542326400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011218","name":"Sandoz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100011218","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4986-1","type":"journal-article","created":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T10:34:22Z","timestamp":1542364462000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOH\u00e9 study)"],"prefix":"10.1186","volume":"18","author":[{"given":"Henri","family":"Roch\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Eymard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abderraouf","family":"Radji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Prevost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafik","family":"Diab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Lamuraglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravaka-Fatoma","family":"Soumoudronga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Gasnereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Toledano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,16]]},"reference":[{"issue":"Suppl 1","key":"4986_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003495-200262001-00001","volume":"62","author":"DC Dale","year":"2002","unstructured":"Dale DC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs. 2002;62(Suppl 1):1\u201315.","journal-title":"Drugs"},{"issue":"Suppl 5","key":"4986_CR2","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/S1098-3597(06)80054-2","volume":"8","author":"GH Lyman","year":"2006","unstructured":"Lyman GH. Risks and consequences of chemotherapy-induced neutropenia. Clin Cornerstone. 2006;8(Suppl 5):S12\u20138.","journal-title":"Clin Cornerstone"},{"key":"4986_CR3","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/cncr.11882","volume":"100","author":"J Crawford","year":"2004","unstructured":"Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100:228\u201337.","journal-title":"Cancer"},{"key":"4986_CR4","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","volume":"90","author":"GH Lyman","year":"2014","unstructured":"Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol. 2014;90:190\u20139.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4986_CR5","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1177\/1078155213492450","volume":"20","author":"D Weycker","year":"2014","unstructured":"Weycker D, Barron R, Kartashov A, Legg J, Lyman GH. Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. J Oncol Pharm Pract. 2014;20:190\u20138.","journal-title":"J Oncol Pharm Pract"},{"key":"4986_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/08977190500055836","volume":"23","author":"AW Roberts","year":"2005","unstructured":"Roberts AW. G-CSF: a key regulator of neutrophil production, but that's not all! Growth Factors. 2005;23:33\u201341.","journal-title":"Growth Factors"},{"key":"4986_CR7","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","volume":"25","author":"NM Kuderer","year":"2007","unstructured":"Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25:3158\u201367.","journal-title":"J Clin Oncol"},{"key":"4986_CR8","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1056\/NEJM199107183250305","volume":"325","author":"J Crawford","year":"1991","unstructured":"Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325:164\u201370.","journal-title":"N Engl J Med"},{"key":"4986_CR9","doi-asserted-by":"crossref","unstructured":"Mhaskar R, Clark OAC, Lyman G, Engel Ayer Botrel T, Morganti Paladini L, Djulbegovic B Colony-stimulating factors for chemotherapy-induced febrile neutropenia Cochrane Database Syst Rev 2014;10:CD003039.","DOI":"10.1002\/14651858.CD003039.pub2"},{"key":"4986_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, Dal LL, Donnelly JP, Kearney N, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8\u201332.","journal-title":"Eur J Cancer"},{"issue":"Suppl 5","key":"4986_CR11","doi-asserted-by":"publisher","first-page":"v248","DOI":"10.1093\/annonc\/mdq195","volume":"21","author":"J Crawford","year":"2010","unstructured":"Crawford J, Caserta C, Roila F, Group EGW. Hematopoietic growth factors: ESMO clinical practice guidelines for the applications. Ann Oncol. 2010;21(Suppl 5):v248\u201351.","journal-title":"Ann Oncol"},{"key":"4986_CR12","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors Version 1.2016."},{"key":"4986_CR13","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33:3199\u2013212.","journal-title":"J Clin Oncol"},{"key":"4986_CR14","unstructured":"European Medicines Agency, CHMP. Guideline on similar biological medicinal products. Revised overarching guideline on biosimilars, 23 October 2014."},{"key":"4986_CR15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1177\/1078155211407367","volume":"18","author":"M Aapro","year":"2012","unstructured":"Aapro M, Cornes P, Abraham I. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. J Oncol Pharm Pract. 2012;18:171\u20139.","journal-title":"J Oncol Pharm Pract"},{"key":"4986_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40259-015-0124-7","volume":"29","author":"F Sorgel","year":"2015","unstructured":"Sorgel F, Schwebig A, Holzmann J, Prasch S, Singh P, Kinzig M. Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics. BioDrugs. 2015;29:123\u201331.","journal-title":"BioDrugs"},{"key":"4986_CR17","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1093\/annonc\/mdp574","volume":"21","author":"P Gascon","year":"2010","unstructured":"Gascon P, Fuhr U, S\u00f6rgel F, Kinzig-Schippers M, Makhson A, Balser S, et al. Development of a new G-CSF product based on biosimilarity assessment. Ann Oncol. 2010;21:1419\u201329.","journal-title":"Ann Oncol"},{"key":"4986_CR18","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1093\/annonc\/mdv281","volume":"26","author":"K Blackwell","year":"2015","unstructured":"Blackwell K, Semiglazov V, Krasnozhon D, Davidenko I, Nelyubina L, Nakov R, et al. Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy. Ann Oncol. 2015;26:1948\u201353.","journal-title":"Ann Oncol"},{"key":"4986_CR19","unstructured":"Zarzio\u00ae Summary of Product Characteristics. Sandoz, Holzkirchen, Germany. \n                    https:\/\/www.ema.europa.eu\/documents\/product-information\/zarzio-epar-product-information_en.pdf\n                    \n                  . Last accessed 28 Oct 2018."},{"key":"4986_CR20","unstructured":"Neupogen\u00ae Summary of Product Characteristics. Amgen Europe BV. \n                    https:\/\/www.medicines.org.uk\/emc\/product\/608\/smpc\n                    \n                  . Last accessed 28 Oct 2018."},{"key":"4986_CR21","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1007\/s00520-013-1911-7","volume":"21","author":"P Gascon","year":"2013","unstructured":"Gascon P, Tesch H, Verpoort K, Rosati MS, Salesi N, Agrawal S, et al. Clinical experience with Zarzio\u00ae in Europe: what have we learned? Support Care Cancer. 2013;21:2925\u201332.","journal-title":"Support Care Cancer"},{"key":"4986_CR22","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1007\/s00520-015-2986-0","volume":"24","author":"S Nahon","year":"2016","unstructured":"Nahon S, Rastkhah M, Ben AM, Soumoudronga RF, Gasnereau I, Labourey JL. Zarzio\u00ae, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study. Support Care Cancer. 2016;24:1991\u20138.","journal-title":"Support Care Cancer"},{"key":"4986_CR23","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00520-015-2861-z","volume":"24","author":"P Gascon","year":"2016","unstructured":"Gascon P, Aapro M, Ludwig H, Bokemeyer C, Boccadoro M, Turner M, et al. Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study). Support Care Cancer. 2016;24:911\u201325.","journal-title":"Support Care Cancer"},{"key":"4986_CR24","unstructured":"US Food and Drug Administration. Approved Drugs - filgrastim-sndz. \n                    https:\/\/www.drugs.com\/history\/zarxio.html\n                    \n                  . Last accessed 25 April 2016."},{"key":"4986_CR25","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/j.1365-2354.2008.00959.x","volume":"18","author":"D Almenar","year":"2009","unstructured":"Almenar D, Mayans J, Juan O, Garcia BJM, Jalon LJI, Frau A, et al. Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain - results of the LEARN study. Eur J Cancer Care. 2009;18:280\u20136.","journal-title":"Eur J Cancer Care"},{"key":"4986_CR26","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1016\/j.ejca.2010.04.031","volume":"46","author":"C Falandry","year":"2010","unstructured":"Falandry C, Campone M, Cartron G, Guerin D, Freyer G. Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines. Eur J Cancer. 2010;46:2389\u201398.","journal-title":"Eur J Cancer"},{"key":"4986_CR27","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/1758834012461330","volume":"4","author":"K Verpoort","year":"2012","unstructured":"Verpoort K, Mohler TM. A non-interventional study of biosimilar granulocyte colony-stimulating factor as prophylaxis for chemotherapy-induced neutropenia in a community oncology Centre. Ther Adv Med Oncol. 2012;4:289\u201393.","journal-title":"Ther Adv Med Oncol"},{"key":"4986_CR28","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.clml.2017.05.002","volume":"17","author":"GL Damaj","year":"2017","unstructured":"Damaj GL, Benbrahim O, Hacini M, Voronina I, Benabed K, Soumoudronga R-F, et al. ZOH\u00e9: A Prospective Study of the Use of Biosimilar Filgrastim Zarzio in Clinical Practice in Patients Treated With Chemotherapy for Lymphoid Malignancies. Clin Lymphoma Myeloma Leuk. 2017;17:362\u20139.e2.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4986_CR29","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s12032-013-0797-z","volume":"31","author":"S Barni","year":"2014","unstructured":"Barni S, Lorusso V, Giordano M, Sogno G, Gamucci T, Santoro A, et al. A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice. Med Oncol. 2014;31:797.","journal-title":"Med Oncol"},{"key":"4986_CR30","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00520-015-2779-5","volume":"24","author":"H Link","year":"2016","unstructured":"Link H, Nietsch J, Kerkmann M, Ortner P, Supportive Care Group of the German Cancer S. Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy--a representative sample survey in Germany. Support Care Cancer. 2016;24:367\u201376.","journal-title":"Support Care Cancer"},{"key":"4986_CR31","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1002\/cam4.454","volume":"4","author":"GH Lyman","year":"2015","unstructured":"Lyman GH, Dale DC, Legg JC, Abella E, Morrow PK, Whittaker S, et al. Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk? Cancer Med. 2015;4:1153\u201360.","journal-title":"Cancer Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4986-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4986-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4986-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T19:10:56Z","timestamp":1573845056000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4986-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,16]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4986"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4986-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,16]]},"assertion":[{"value":"10 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval and data protection approval of the ZOH\u00e9 study were authorised by the Comit\u00e9 Consultatif sur le Traitement d\u2019Information en mati\u00e8re de Recherche dans le domaine de la Sant\u00e9 (CCTIRS, the French national advisory committee on information processing of research materials in health studies) and the Commission Nationale de l\u2019lnformatique et des Libert\u00e9s (CNIL, the French independent national data protection authority), as required by French law for observational research regulation. Informed patient consent was obtained verbally prior to study participation as this was an observational study using a conventional treatment. An information note was shared with all eligible patients to inform consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors received funding from Sandoz for the conduct of the study in their institutions. Additionally, RD has acted on advisory boards for Sanofi, and received research funding from Cephalon, Hospira, Sandoz, Roche, and Teva. JCE has been a board member for Astellas, Janssen, Novartis and Sanofi, and has received research funding from Novartis, Sandoz and Teva. HR, AP, ML and AT have no further conflicts of interest to declare. RFS and IG are employed by Sandoz.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"1127"}}